How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD

This video interview features Steven Nissen, MD, telling his 2007 story of revealing that the number-1 diabetes drug, rosiglitazone, led to more cardiovascular events than placebo or a variety of competitors. The discovery resulted in new requirements for clinical trials to rule out harm. It focuses...

Descripción completa

Detalles Bibliográficos
Autores principales: Nissen, Steven E., Young, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Houston Methodist DeBakey Heart & Vascular Center 2022
Materias:
Interview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733186/
https://www.ncbi.nlm.nih.gov/pubmed/36561089
http://dx.doi.org/10.14797/mdcvj.1181
_version_ 1784846309571690496
author Nissen, Steven E.
Young, James B.
author_facet Nissen, Steven E.
Young, James B.
author_sort Nissen, Steven E.
collection PubMed
description This video interview features Steven Nissen, MD, telling his 2007 story of revealing that the number-1 diabetes drug, rosiglitazone, led to more cardiovascular events than placebo or a variety of competitors. The discovery resulted in new requirements for clinical trials to rule out harm. It focuses on how a new understanding of drug or drug class pharmacology often drives drug development, and includes a discussion of the approval process, which may bring a different result than was originally intended. View the video at https://youtu.be/aFtCfZyd54E.
format Online
Article
Text
id pubmed-9733186
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Houston Methodist DeBakey Heart & Vascular Center
record_format MEDLINE/PubMed
spelling pubmed-97331862022-12-21 How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD Nissen, Steven E. Young, James B. Methodist Debakey Cardiovasc J Interview This video interview features Steven Nissen, MD, telling his 2007 story of revealing that the number-1 diabetes drug, rosiglitazone, led to more cardiovascular events than placebo or a variety of competitors. The discovery resulted in new requirements for clinical trials to rule out harm. It focuses on how a new understanding of drug or drug class pharmacology often drives drug development, and includes a discussion of the approval process, which may bring a different result than was originally intended. View the video at https://youtu.be/aFtCfZyd54E. Houston Methodist DeBakey Heart & Vascular Center 2022-12-06 /pmc/articles/PMC9733186/ /pubmed/36561089 http://dx.doi.org/10.14797/mdcvj.1181 Text en Copyright: © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.
spellingShingle Interview
Nissen, Steven E.
Young, James B.
How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
title How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
title_full How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
title_fullStr How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
title_full_unstemmed How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
title_short How a New Understanding of Drug or Drug Class Pharmacology Often Drives Drug Development: A Conversation with Steven E. Nissen, MD
title_sort how a new understanding of drug or drug class pharmacology often drives drug development: a conversation with steven e. nissen, md
topic Interview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733186/
https://www.ncbi.nlm.nih.gov/pubmed/36561089
http://dx.doi.org/10.14797/mdcvj.1181
work_keys_str_mv AT nissenstevene howanewunderstandingofdrugordrugclasspharmacologyoftendrivesdrugdevelopmentaconversationwithstevenenissenmd
AT youngjamesb howanewunderstandingofdrugordrugclasspharmacologyoftendrivesdrugdevelopmentaconversationwithstevenenissenmd

Ejemplares similares